|02/05/15||Safety and Preliminary Efficacy of Human Neural Stem Cells in StemCells, Inc.'s Dry AMD Study to be Presented at Ophthalmology Conference|
|NEWARK, Calif., Feb. 5, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing novel cell-based therapeutics for disorders of the central nervous system, announced today that Theodore Leng, MD, MS, Clinical Assistant Professor of Ophthalmology at the Byers Eye Institute at Stanford, Stanford University School of Medicine and a principal investigator on StemCells, Inc.'s Phase I/II study in dry age related macular degeneration will be presenting findings on... |
|02/02/15||StemCells, Inc. to Participate at the 17th Annual BIO CEO & Investor Conference|
|Management Will Present an Update on the Company's Programs, Pipeline and Operations
NEWARK, Calif., Feb. 2, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that Management will make a presentation on the Company's programs and operations at the 17th Annual BIO CEO & Investor Conference. Management is scheduled to speak at 8:30 a.m. EST on Monday, February 9, at the Waldorf Astoria in New York City.
A live webcast of the presentations will be available through the... |
|01/26/15||StemCells, Inc. Posts Letter to Shareholders|
|NEWARK, Calif., Jan. 26, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing novel cell-based therapeutics for disorders of the central nervous system, posted today the following Letter to Shareholders from its President and CEO, Martin McGlynn.
January 26, 2015
Dear Fellow Shareholders:
Over the past year, StemCells, Inc. has made substantial progress. We completed enrollment and dosing in our Phase I/II clinical trials in two major indicat... |